Duration of GnRH Agonist Treatment for Uterine Fibroids Before Surgery

Efficacy and Recommendations

The American College of Radiology recommends GnRH agonists as effective second-line options that both reduce bleeding symptoms and significantly reduce fibroid volume 1, 3
GnRH agonists can reduce fibroid volume by 18-30% and significantly improve preoperative hemoglobin levels in patients with uterine fibroids 1, 2, 3

For a uterus of 12 weeks gravid size with multiple fibroids or a single large fibroid, a 3-month course of GnRH agonist is recommended before surgery to achieve optimal balance between significant volume reduction and minimizing side effects 1

GnRH agonist monotherapy causes hypoestrogenic effects including hot flashes, headaches, hypertension, and bone mineral density loss in patients undergoing treatment for uterine fibroids 1, 4
Consider combination treatment with low-dose estrogen and progestin (add-back therapy) to mitigate hypoestrogenic side effects while maintaining therapeutic efficacy in patients with uterine fibroids 1, 4
Add-back therapy is FDA-approved in combination with GnRH agonists for fibroid-related heavy menstrual bleeding 4

Alternative options for preoperative treatment include ulipristal acetate (a selective progesterone receptor modulator), though its availability in the US is limited due to hepatotoxicity concerns 1